$0.72 EPS Expected for Masimo Co. (MASI) This Quarter

Equities analysts predict that Masimo Co. (NASDAQ:MASI) will post earnings of $0.72 per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Masimo’s earnings. The highest EPS estimate is $0.74 and the lowest is $0.70. Masimo posted earnings per share of $0.83 in the same quarter last year, which would suggest a negative year-over-year growth rate of 13.3%. The company is expected to report its next quarterly earnings report on Wednesday, August 1st.

On average, analysts expect that Masimo will report full-year earnings of $2.89 per share for the current year, with EPS estimates ranging from $2.88 to $2.89. For the next year, analysts anticipate that the firm will report earnings of $2.98 per share, with EPS estimates ranging from $2.92 to $3.03. Zacks’ EPS calculations are an average based on a survey of research firms that follow Masimo.

Masimo (NASDAQ:MASI) last posted its quarterly earnings results on Wednesday, May 2nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.69 by $0.06. The company had revenue of $212.90 million for the quarter, compared to analysts’ expectations of $205.65 million. Masimo had a return on equity of 23.14% and a net margin of 15.99%. The firm’s revenue was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.57 earnings per share.

Several analysts have issued reports on the stock. ValuEngine downgraded shares of Masimo from a “buy” rating to a “hold” rating in a research note on Thursday, June 7th. BidaskClub raised shares of Masimo from a “buy” rating to a “strong-buy” rating in a research note on Thursday, May 31st. Zacks Investment Research downgraded shares of Masimo from a “buy” rating to a “hold” rating in a research note on Monday, May 7th. BTIG Research reissued a “buy” rating and set a $100.00 target price on shares of Masimo in a research note on Thursday, May 3rd. Finally, Piper Jaffray Companies boosted their target price on shares of Masimo to $94.00 and gave the company a “neutral” rating in a research note on Wednesday, May 2nd. Three investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. Masimo has an average rating of “Buy” and a consensus target price of $101.17.

In other Masimo news, insider Jon Coleman sold 29,303 shares of the business’s stock in a transaction on Thursday, March 29th. The shares were sold at an average price of $87.50, for a total transaction of $2,564,012.50. Following the sale, the insider now directly owns 20,504 shares of the company’s stock, valued at approximately $1,794,100. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Sanford Fitch sold 2,000 shares of the business’s stock in a transaction on Monday, April 2nd. The shares were sold at an average price of $86.02, for a total transaction of $172,040.00. Following the transaction, the director now owns 66,249 shares in the company, valued at $5,698,738.98. The disclosure for this sale can be found here. Over the last three months, insiders have sold 137,203 shares of company stock worth $12,640,110. Company insiders own 12.60% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Intrust Bank NA grew its holdings in shares of Masimo by 15.5% during the 1st quarter. Intrust Bank NA now owns 4,490 shares of the medical equipment provider’s stock valued at $395,000 after acquiring an additional 603 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. grew its holdings in shares of Masimo by 7.4% during the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 10,368 shares of the medical equipment provider’s stock valued at $879,000 after acquiring an additional 718 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Masimo by 39.7% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,820 shares of the medical equipment provider’s stock valued at $239,000 after acquiring an additional 802 shares in the last quarter. Brown Capital Management LLC grew its holdings in shares of Masimo by 0.8% during the 4th quarter. Brown Capital Management LLC now owns 98,506 shares of the medical equipment provider’s stock valued at $8,353,000 after acquiring an additional 819 shares in the last quarter. Finally, Eagle Asset Management Inc. grew its holdings in shares of Masimo by 2.8% during the 4th quarter. Eagle Asset Management Inc. now owns 33,704 shares of the medical equipment provider’s stock valued at $2,858,000 after acquiring an additional 932 shares in the last quarter. Institutional investors and hedge funds own 83.77% of the company’s stock.

Shares of NASDAQ MASI traded up $0.62 during trading on Friday, hitting $101.54. The company had a trading volume of 412,243 shares, compared to its average volume of 507,466. The stock has a market capitalization of $5.24 billion, a P/E ratio of 41.44, a P/E/G ratio of 2.41 and a beta of 0.95. Masimo has a 52 week low of $80.69 and a 52 week high of $102.32.

About Masimo

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Get a free copy of the Zacks research report on Masimo (MASI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply